Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States December 19, 2014
Novocure Announces FDA Approval of an IDE Supplement Allowing All Control Patients in its Phase III Trial in Newly Diagnosed GBM to Cross Over to Receive Tumor Treating Fields December 02, 2014
Interim Analysis of Novocure’s Phase III Trial in Newly Diagnosed Glioblastoma to be Presented at Japan Society For Neuro-Oncology 2014 December 01, 2014
